Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
edasalonexent (Astria Therapeutics)
- Development stage
- Discontinued
- Lead developer
- Astria Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Edasalonexent (CAT-1004) is an orally bioavailable small molecule conjugate of salsalate and docosahexaenoic acid (DHA) developed by Catabasis Pharmaceuticals (now Astria Therapeutics). It was designed using the company's SMART (Salsalate-Macromolecule-Activated-Release-Technology) platform to synergistically inhibit the NF-κB pathway. NF-κB is a key driver of skeletal and cardiac muscle degeneration in Duchenne muscular dystrophy (DMD). By delivering both salsalate (an IKKβ inhibitor) and DHA (an omega-3 fatty acid) in a single molecule, edasalonexent aimed to reduce inflammation and promote muscle regeneration. Despite promising early-phase results, the drug failed to meet its primary and secondary endpoints in the Phase 3 PolarisDMD trial, leading to the discontinuation of its development for DMD in 2020.
- Other names
- salsalate + docosahexaenoic acidsalsalate-DHA conjugate
02
Targets
FPR2 (Formyl peptide receptor type 2)CMKLR1 (Chemokine-like receptor 1)LTB4R (Leukotriene B4 Receptor 1)GPR32 (G protein-coupled receptor 32)PGHS-1 (Prostaglandin G/H Synthase 1)ELIC (Erwinia ligand-gated ion channel)CBP/p300 (CREB-binding protein / E1A-associated protein p300)
Beyond the preview
Go deeper on edasalonexent (Astria Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on edasalonexent (Astria Therapeutics).